Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELTX
Strong SellSinkerElicio Therapeutics, Inc. · Healthcare · United States · $75M · Avg Vol: $634K/d
COMPANY DESCRIPTION
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing its proprietary AMP (Amphiphile) technology platform. The company's lead product candidate, ELI-002, is an 'amph-modified' vaccine designed to boost immune responses to KRAS-mutated cancers. Elicio's competitive edge lies in its innovative approach to enhance cancer immunotherapies by precisely targeting lymph nodes to activate immune cells.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.90 | -2.54 | -1.78 | -2.58 | — | -2.15 | -1.95 | -2.17 | — |
| Shares | 26.3M | 26.3M | 26.3M | 17.8M | -32.2% | — | — | — | — |
| Debt | 7.5M | 6.9M | 26.0M | 14.5M | 24.7% | 14.1M | — | — | — |
| Equity | -102.1M | 11.4M | -11.3M | 1.6M | -62.1% | — | — | — | — |
| Op CF | -22.2M | -32.7M | -37.1M | -37.0M | — | -37.7M | — | — | — |
| Inv CF | -0.7M | -32.0K | -84.0K | -16.0K | — | — | — | — | — |
| Fin CF | 21.2M | 38.6M | 42.3M | 36.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELTX | Elicio Therapeutics, Inc.(you) | $75M | 2 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| ESLA | Estrella Immunopharma, Inc. | $62M | 1 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%